IN VIVO ASSESSMENT OF PREVENTION OF LUNG FIBROSIS USING THE PAN-PPAR AGONIST LANIFIBRANOR IN THE TBRIIDK-FIB MOUSE MODEL OF SYSTEMIC SCLEROSIS-MedSci.cn

IN VIVO ASSESSMENT OF PREVENTION OF LUNG FIBROSIS USING THE PAN-PPAR AGONIST LANIFIBRANOR IN THE TBRIIDK-FIB MOUSE MODEL OF SYSTEMIC SCLEROSIS

Derrett-Smith, E; Xu, SW; Abraham, D; Lacombe, O; Broqua, P; Junien, JL; Konstantinova, I; Denton, CP

RHEUMATOLOGY, 2019; 58 (): 25

科室
- - 订阅+
  - 更多科室
工具
服务